Dihydroergotamine mesylate and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Dihydroergotamine mesylate (dihydroergotamine mesylate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Indomethacin, and have Migraine.

The phase IV clinical study analyzes which people have Weakness when taking Dihydroergotamine mesylate. It is created by eHealthMe based on reports of 792 people who have side effects when taking Dihydroergotamine mesylate from the FDA, and is updated regularly.

What is Dihydroergotamine mesylate?

Dihydroergotamine mesylate has active ingredients of dihydroergotamine mesylate. eHealthMe is studying from 807 Dihydroergotamine mesylate users. Check the latest studies of Dihydroergotamine mesylate.

What is Weakness?

Weakness is found to be associated with 3,638 drugs and 6,618 conditions by eHealthMe. Check the latest studies of Weakness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

792 people reported to have side effects when taking Dihydroergotamine mesylate.
Among them, 49 people (6.19%) have Weakness.

Could Dihydroergotamine mesylate cause Weakness?

Among these 49 people:

How long have people been on Dihydroergotamine mesylate when they have Weakness? *

What is the gender of people who have Weakness when taking Dihydroergotamine mesylate? *

female: 93.75 %
male: 6.25 %

What is the age of people who have Weakness when taking Dihydroergotamine mesylate? *

What are other drugs people take besides Dihydroergotamine mesylate? *

Estradiol: 30 people, 61.22%
Ketoprofen: 30 people, 61.22%
Paroxetine Hydrochloride: 30 people, 61.22%
Prazepam: 30 people, 61.22%
Amitriptyline Hydrochloride: 30 people, 61.22%
Almotriptan Malate: 30 people, 61.22%
Topiramate: 30 people, 61.22%
Singulair: 30 people, 61.22%
Keppra: 30 people, 61.22%
Indomethacin: 30 people, 61.22%

What are other side effects people have besides Weakness? *

Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 38 people, 77.55%
Fatigue (feeling of tiredness): 36 people, 73.47%
Gait Disturbance: 34 people, 69.39%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 32 people, 65.31%
Pain: 32 people, 65.31%
Headache (pain in head): 32 people, 65.31%
Diplopia (double vision): 32 people, 65.31%
General Physical Health Deterioration (weak health status): 31 people, 63.27%
Night Sweats (sweating in night): 31 people, 63.27%
Nausea (feeling of having an urge to vomit): 31 people, 63.27%

What are the existing conditions these people have? *

Migraine (headache): 38 people, 77.55%
Headache (pain in head): 34 people, 69.39%
Excessive Or Unwanted Hair In Women: 30 people, 61.22%
Haemorrhage (bleeding): 30 people, 61.22%
Vaginal Bleeding Between Periods: 30 people, 61.22%
Asthma: 30 people, 61.22%
Dysmenorrhea (painful menstruation): 28 people, 57.14%
Hair Disorder: 25 people, 51.02%
Ovarian Cysts (fluid filled sacs of the ovary): 20 people, 40.82%
Birth Control: 19 people, 38.78%

* Approximation only. Some reports may have incomplete information.

Do you take Dihydroergotamine mesylate and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dihydroergotamine mesylate:

Dihydroergotamine mesylate (807 reports)

Weakness treatments and more:

Weakness (586,877 reports)

Browse all side effects of Dihydroergotamine mesylate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,638 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,618 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dihydroergotamine mesylate (the active ingredients of Dihydroergotamine mesylate) and Dihydroergotamine mesylate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.